Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Uprosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 6/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 6/20 | 1.00 |
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | SGK1 | O00141 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uprosertib SCHEMBL168584 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| Uprosertib SCHEMBL18825699 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL25062541 | 0.94 | AKT1 (0.89) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL14823114 | 0.93 | AKT1 (0.87) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529493 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529507 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529610 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529392 | 0.90 | AKT1 (0.81) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL22827778 | 0.89 | AKT1 (0.80) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529501 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041666-A1 | MITOGEN SIGNALLING PATHWAY PROTEIN VARIANTS | GENOME RESEARCH LIMITED (GB) | 2026-02-26 | — | — | WO | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615431-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4604957-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| CN-120051280-A | Combination of SERD for treating cancer | 阿斯利康(瑞典)有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4519418-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431581-A | Antigen binding proteins | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250041293-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | GENOME RESEARCH LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| WO-2022234003-A1 | CD33 BINDING POLYPEPTIDES WITH STEFIN A PROTEIN | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| EP-4077329-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Imperial College Innovations Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022208353-A1 | ANTIGEN BINDING PROTEINS AND COMBINATIONS THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022204368-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-109789316-B | Compositions and methods for treating lysosomal storage disorders and disorders characterized by lysosomal dysfunction | 贝勒医学院 | 2022-09-27 | — | — | CN | disclosed |
| WO-2022198141-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022185160-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
| EP-4034562-A2 | ANTIGEN BINDING PROTEINS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-08-03 | — | — | EP | disclosed |
| CN-114729049-A | Antigen binding proteins | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | AKT1 327/4885AKT2 591/4885AKT3 709/4885 |
| US-20250041293-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | IGF1R, IRS1, IGFBP1 | AKT1 78/4885AKT2 46/4885AKT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.